Adial Pharmaceuticals said the patent was awarded by the United States Patent and Trademark Office on Feb. 20 and covers the company's lead investigational new drug product, AD04, and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder. Benzinga broke the news first Wednesday morning with an exclusive report before the opening bell.
Okta reported quarterly earnings of 63 cents per share which beat the analyst consensus estimate of 51 cents. Quarterly sales came in at $605 million which beat the analyst consensus estimate of $587.5 million and is a 18.63% increase over sales of $510 million from the same period last year. Subscription backlog was $3.385 billion, an increase of 13% year-over-year and cRPO, which is subscription backlog expected to be recognized over the next 12 months, was $1.952 billion, up 16% year-over-year.
Director Oprah Winfrey has decided not to stand for re-election to the WeightWatchers board of directors. She has served on the board since 2015. "I look forward to continuing to advise and collaborate with WeightWatchers and CEO Sima Sistani in elevating the conversation around recognizing obesity as a chronic condition, working to reduce stigma, and advocating for health equity," said Oprah Winfrey.